From:

Subject: FW: PT position - CBD and other cannabis ingredients

Date: vendredi 29 avril 2022 16:18:43

Attachments: <u>image001.png</u>

PT contribution CBD in cosmetics v01.pdf Cannabidiol Adverse Effects and Toxicity.pdf Circular Informativa N.º014 CD 100.20.200.pdf

Conversion of Cannabidiol (CBD) into Psychotropic cannabinoids.pdf

Pharmacokinetics of cannabidiol in dogs.pdf Safety and Side Effects of Cannabidiol.pdf Transdermal pharmacokinetics.pdf

Translation of portuguese information circular.pdf

veroushalmi2020.pdf

Importance: High

Dear All,

In accordance with the follow-up actions established during the last Working Group on Cosmetic Products (March 1, 2022) and reinforced in the Standing Committee, Portugal attaches to this email several documents that are its contribution, at this moment of the discussion, on the topic of CBD and other cannabis ingredients.

We attach to this email the following:

Contribution to the discussion - a document that analyzes the current use of CBD and its potential risks;

INFARMED Orientation "Informative Circular" and its translation; some articles published in peer-reviewed journals that were used to support the Portuguese position (circulation should be limited to Member states due to copyright)

With the member state where the production of cannabis is authorized and controlled for medical purposes, we have been a field of discussion on this topic.

We believe it is important that all the aspects mentioned in the document are considered and that member states are able to reach a joint and coherent position.

Finally, we recommend consulting the SCCS with all the support material collected.

Best Regards,

Direção de Produtos de Saúde Health Products Directorate cid:image005.png@01D608E5.80492AA0



INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.

INFARMED - National Authority of Medicines and Health Products, I.P.

Parque de Saúde de Lisboa - Avenida do Brasil, 53

1749-004 Lisboa - Portugal